As SR9243 showed an ability to stimulate CD8 + inflammatory activity we decided to explore if LXR blockade can stimulate CD8+ T-cell clonal expansion, which is vital to mounting an effective anti-tumor immune response. Here, CD8A is linked to neoplasm.